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Abstract
Wnt/b-catenin signaling plays a major role in embryonic development and adult stem cell maintenance. Reduced activation
of the Wnt/b-catenin pathway underlies neurodegenerative disorders and aberrations in bone formation. Screening of a
small molecule compound library with a b-galactosidase fragment complementation assay measuring b-catenin nuclear
entry revealed bona fide activators of b-catenin signaling. The compounds stabilized cytoplasmic b-catenin and activated b–
catenin-dependent reporter gene activity. Although the mechanism through which the compounds activate b-catenin
signaling has yet to be determined, several key regulators of Wnt/b-catenin signaling, including glycogen synthase kinase 3
and Frizzled receptors, were excluded as the molecular target. The compounds displayed remarkable selectivity, as they
only induced b-catenin signaling in a human osteosarcoma U2OS cell line and not in a variety of other cell lines examined.
Our data indicate that differences in cellular Wnt/b-catenin signaling machinery can be exploited to identify cell type-
specific activators of Wnt/b-catenin signaling.
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Introduction
Wnt/b-catenin signaling orchestrates embryogenesis and adult
stem cell maintenance in mammals [1]. It is initiated when Wnt
ligands bind to seven transmembrane receptors of the Frizzled
family and to representatives of the single-pass low-density
lipoprotein receptor-related protein family (LRP5 or -6) [2,3,4].
Wnt, Frizzled and LRP5/6 form a ternary complex that initiates a
cascade of molecular interactions that ultimately leads to the
cytoplasmic stabilization of the transcriptional modulator b-
catenin. b-Catenin subsequently enters the nucleus where it
interacts with T cell factor/Lymphoid enhancer factor (TCF/LEF)
and influences the transcription of b-catenin-dependent genes [5].
In non-stimulated cells, b-catenin protein stability is compromised
by the glycogen synthase kinase 3 (GSK3)-mediated phosphory-
lation of b-catenin on several conserved N-terminal residues.
These phosphorylations serve as cues for proteasomal degradation
of b-catenin. As a result, quiescent cells typically contain low levels
of cytoplasmic and nuclear b-catenin.
Aberrations in Wnt/b-catenin signaling activity are associated
with several malignancies [6]. For example, mutations that lead to
increased b-catenin stability are observed in the large majority of
colon cancers [6], and drug discovery efforts have mainly focused
on identifying inhibitors for the b-catenin pathway [7]. The
potential medical application of activators of b-catenin signaling
has been largely overlooked, despite evidence that reduced
b-catenin signaling underlies neurodegenerative disorders and
aberrations in bone formation [8,9]. We have previously described
a cell-based assay that measures the nuclear translocation of b-
catenin using enzyme fragment complementation (EFC) [10]. In
this assay, complementation occurs between a peptide fragment of
b-galactosidase (called a-peptide) that is genetically fused to b-
catenin and a nuclear-resident complementary enzyme fragment
(termed Da-Nuc). By applying this assay to screening of a low
molecular weight compound library, we have identified novel
activators of b-catenin signaling.
Results
We tested 2300 drug-like compounds with activity towards G
protein-coupled receptors (GPCR) or kinases for their ability to
activate Wnt/b-catenin signaling in a human osteosarcoma U2OS
cell line (termed U2OS-EFC) genetically engineered to couple
nuclear entry of b-catenin to increases in b-galactosidase
complementation [10] and found three hits. One of these was
sotrastaurin (AEB-071), an anti-inflammatory drug that was found
to inhibit GSK3 [10]. The other two hits, denoted Cpd1 and
Cpd2 (Figure 1A), did not inhibit GSK3 or any other kinase in a
panel of more than 200 kinases tested at 10 mM in biochemical
assays (performed at Millipore; data not shown). Cpd 1 and 2
(Figure 1B) have been described previously as cannabinoid CB2
receptor agonists in a patent application (WO2010/063666) [11].
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To investigate whether the cannabinoid CB2 receptor was
involved in the activation of Wnt/b-catenin signaling, reference
cannabinoid CB1/2 agonists CP-55940, WIN55,212-2, and
several structural analogs of Cpd1 and Cpd2 were tested in the
assay. However, none of these potent cannabinoid CB2 agonists
exerted any significant effect (Figure 1A), indicating that the effect
was compound specific and activation of the cannabinoid CB2
receptors was not the mechanism through which Cpd1 and Cpd2
increased b–galactosidase activity in the assay.
At a 10 mM concentration, both Cpd1 and Cpd2 induced
transcription of a transiently transfected SuperTOPflash reporter
gene in U2OS-EFC cells (Figure 1C). We observed micromolar
potencies for both compounds (data not shown), similar to those
observed in the EFC assay (Figure 1A). As controls, we treated
these cells with 12 nM recombinant mouse Wnt-3a (rmWnt-3a)
and 30 mM lithium chloride (LiCl) (Figure 1C). Wnt-3a is a
naturally occurring Wnt ligand that activates Wnt/b-catenin
signaling in several contexts [12,13]. LiCl and MG132 (see below)
inhibit GSK3 and the proteasome, respectively. Treating cells with
these agents causes b-catenin stabilization and subsequent
activation of Wnt/b-catenin signaling [10]. Cpd1 and Cpd2 did
not induce transcription of a mutant luciferase reporter gene
construct containing b-catenin-responsive elements that do not
bind TCF (SuperFOPflash; Figure 1C), demonstrating selectivity
of the response. We subsequently studied the cytoplasmic
accumulation of b-catenin in U2OS-EFC cells following a three
hour treatment with rmWnt-3a, LiCl, sotrastaurin and MG132.
As predicted, these treatments resulted in an increase in
Figure 1. Cpd1 and Cpd2 activate Wnt/b-catenin signaling in U2OS-EFC cells. (A) U2OS-EFC cells were treated with vehicle, 12 nM rmWnt-
3a or increasing concentrations of Cpd1, Cpd2 and CP-55940 for 3 hrs, followed by measurement of b-galactosidase activity. (B) Structures of Cpd1
and Cpd2. (C) U2OS-EFC cells transiently transfected with SuperTOPflash (white bars) or SuperFOPflash (black bars) reporter gene construct were
incubated with vehicle, 12 nM rmWnt-3a, 30 mM lithium chloride (LiCl) or 10 mM Cpd1, Cpd2 or CP-55940 for 5 hrs before measurement of luciferase
activity. (D) U2OS-EFC cells were treated with vehicle, 12 nM rmWnt-3a, 30 mM LiCl, 20 mMMG132 or 10 mM sotrastaurin, Cpd1, Cpd2 or CP-55940 for
3 hrs. Cytoplasmic protein fractions were isolated and subjected to western blotting for b-catenin and b-actin. (E) U2OS-EFC cells were treated with
vehicle, 12 nM rmWnt-3a or 10 mM Cpd1 for 8 hrs before analysis of axin2 mRNA levels relative to the expression of the housekeeping gene TATA
box-binding protein (TAFII) by means of qPCR. Asterisks (*) represent statistically significant differences (P,0.05).
doi:10.1371/journal.pone.0019185.g001
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cytoplasmic levels of both non-modified (92 kDa) and a-peptide-
tagged (96 kDa) b-catenin, as assessed by Western blotting
(Figure 1D). Cpd1 and Cpd2 also stabilized cytoplasmic b-catenin,
whereas CP-55940 did not (Figure 1D). Finally, qPCR analysis
showed that the mRNA levels of the b-catenin-responsive gene
axin2 [14,15] were up-regulated by treatment with Cpd1 in
U2OS-EFC cells (Figure 1E) and in U2OS-Da-Nuc cells (Figure
S1), which are the parental cells of U2OS-EFC cells.
Because Frizzleds are structurally related to GPCRs, we
investigated whether Cpd1 and Cpd2 are capable of activating
Frizzleds. To assess this, we used recombinant human Dickkopf-1
(rhDkk-1) protein, which recruits LRP5/6 to the membrane
protein Kremen, leading to internalization of LRP5/6 [16,17].
This causes cells to become unresponsive to Wnts. We confirmed
desensitization by incubating U2OS-EFC cells with increasing
concentrations of rhDkk-1 in the presence of 10 nM rmWnt-3a.
As can be seen in Figure 2A, rhDkk-1 dose-dependently decreased
b-catenin signaling induced by rmWnt-3a. However, 2 mg/ml
rhDkk-1 did not reduce b-galactosidase activity induced by Cpd1
or Cpd2, whereas it reduced rmWnt-3a-induced signaling to
background levels (Figure 2B). Furthermore, Cpd1 and Cpd2 did
not induce phosphorylation of LRP6 at Ser1490 (Figure 2C), an
early event during Wnt/b-catenin pathway activation [18,19].
This suggests that both compounds interact with Wnt/b-catenin
signaling at a level between LRP5/6 receptor activation and
cytoplasmic accumulation of b-catenin.
Although biochemical profiling indicated that Cpd1 or Cpd2
did not act through inhibition of GSK3 or any other protein
kinase, the possibility that the compounds inhibit GSK3 activity by
inducing phosphorylation of an N-terminal serine residue (Ser21
in GSK3a and Ser9 in GSK3b) can only be verified in cells.
Phosphorylation of GSK3b at Ser9 is catalyzed by protein kinase
B (PKB)/Akt, when cells are stimulated with insulin or platelet-
derived growth factor (PDGF) [20]. To investigate whether Cpd1
and Cpd2 could induce GSK3b phosphorylation at Ser9, U2OS-
EFC cells were treated for 30 min with 100 nM insulin, 100 ng/
ml PDGF, or 10 mMCpd1 or Cpd2. As is apparent from Figure 3,
insulin and PDGF induced a marked increase in the phosphor-
ylation of PKB/Akt at Ser473 and of GSK3b at Ser9. However,
Cpd1 and Cpd2 did not induce PKB/Akt or GSK3b phosphor-
ylation (Figure 3). These results suggest that Cpd1 and Cpd2 do
not affect GSK3 function. Thus, our data demonstrate that Cpd1
and Cpd2 activate Wnt/b-catenin signaling upstream of b-catenin
stabilization and downstream of LRP5/6 phosphorylation (Figure
S2).
696 structural analogs of Cpd1 and Cpd2 were selected from
the Merck research Laboratories compound library and tested in
the b-catenin EFC assay. 18 compounds were found to increase b-
galactosidase activity at 10 mM and two compounds (Cpd4 and 5
in Figure S3) were even more efficacious than Cpd1. There was no
apparent correlation between biophysical parameters, such as
solubility or lipophylicity, and activity in the b-catenin EFC assay
(data not shown), indicating that the activity in the assay was
through interaction with a specific target. We have attempted to
identify the target by profiling Cpd1 against 80 GPCR-,
transporter- and ion channel targets (performed at Cerep, Paris,
France) and 21 human phosphatases (performed at Millipore), but
these screens did not reveal any specific interactions that could
Figure 2. Cpd1 and Cpd2 do not activate Frizzleds. (A) U2OS-EFC cells were treated with vehicle or 10 nM rmWnt-3a in the absence or
presence of increasing concentrations of rhDkk-1 for 3 hrs, followed by measurement of b-galactosidase activity. (B) U2OS-EFC cells were stimulated
with 10 nM rmWnt-3a, 30 mM LiCl, 20 mM MG132 or 10 mM sotrastaurin, Cpd1 and Cpd2 in the presence of absence of 48 nM rhDkk-1 for 3 hrs, after
which b-galactosidase activities were measured. (C) U2OS-EFC cells were treated with vehicle, 12 nM rmWnt-3a, 30 mM LiCl or 10 mM Cpd1, Cpd2,
Win55,512-2 and CP-55940 for 1 hr, followed by cell lysis and western blotting for b-actin, total LRP6 and LRP6 phosphorylated at Ser1490. Asterisks
(*) represent statistically significant differences (P,0.05).
doi:10.1371/journal.pone.0019185.g002
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account for the activating effect of Cpd1 on b-catenin signaling in
our cell-based assays.
We extended our analysis of Cpd1/2 to different cell lines by
transient transfection of superTOPflash reporter gene construct,
followed by treatment with compound. As expected, U2OS-Da-
Nuc cells responded to Cpd1 and Cpd2 with a marked increase in
reporter gene activity (Figure 4A). In contrast, the superTOPflash
reporter was not activated in human embryonic kidney
(HEK293T) cells, cervical cancer (HeLa) cells or Chinese hamster
ovary (CHO-K1) cells after Cpd1/2 treatment (Figure 4B, Figure
S4A,B). Consistent with these findings, cytoplasmic b-catenin
levels of HEK293T cells were not increased by treatment with
10 mM Cpd1 or Cpd2 (Figure 4C). Notably, Cpd1 and Cpd2 did
not activate reporter gene activity in another human osteosarcoma
cell line (Saos2), or in a rat osteosarcoma (UMR106) cell line
(Figure S4C,D). Most strikingly, the compounds were inactive in a
U2OS cell batch directly obtained from the American Type
Culture Collection (ATCC; Figure S4E). We confirmed that the
U2OS-EFC cells shared a common ancestry with the U2OS cells
from ATCC by microsatellite analysis, although the analysis
indicated that genetic drift had occurred (performed at Biore-
liance, Glasgow, UK; data not shown).
Despite the absence of b-catenin activation in any cell line other
than U2OS-EFC cells and U2OS-Da-Nuc cells, our data do not
suggest that activation of b-galactosidase activity by Cpd1 and
Cpd2 is an assay artifact. Firstly, other parameters of Wnt/b-
catenin signaling, such as b-catenin-dependent reporter genes and
Western blotting of cytoplasmic b-catenin levels also imply
activation of Wnt/b-catenin signaling in these cells (Figure 1C–
E, Figure 4A). As an additional control experiment, we transfected
U2OS-Da-Nuc cells with luciferase reporter genes sensitive to
cAMP (CREB), Ca2+ (NFAT) and glucocorticoid hormone
receptor (GR) signaling. None of these reporter genes was
activated by Cpd1, whereas SuperTOPflash reporter gene activity
was dose-dependently induced by Cpd1 treatment (Figure S5A–
D). Furthermore, HEK293 cells engineered to complement b-
galactosidase in response to rmWnt-3a (HEK293-EFC cells) did
not activate b-catenin signaling when treated with Cpd1 or Cpd2
(Figure 4D). In addition, Cpd1 did not induce b-galactosidase
activity in a cellular EFC assay for the recruitment of the
scaffolding protein b-arrestin2 to human parathyroid hormone
receptor 1 (Figure S6). Furthermore, Cpd1 did not induce the
nuclear translocation of human GR in U2OS cells (U2OS-GR)
genetically engineered to complement b-galactosidase in response
to GR agonists [10], such as dexamethasone (Dex; Figure 4E). Of
note, U2OS-GR cells are derivatives of the U2OS-Da-Nuc cell
line. Lastly, time-course EFC experiments revealed that the onset
of signal generation in U2OS-EFC cells stimulated with 10 mM
Cpd1 is similar to that generated in U2OS-EFC cells treated with
500 ng/ml rmWnt-3a (Figure 4F), although b-galactosidase
activity in response to rmWnt-3a seems to reach a plateau earlier.
A signal generation profile similar to that seen for Cpd1 was
observed when U2OS-EFC cells were treated with 30 mM LiCl
(Figure S7). All these experiments indicate that Cpd1/2’s ability to
activate Wnt/b-catenin is a highly specific, cell-type dependent
process.
Discussion
Activation of the Wnt/b-catenin pathway might provide a new
therapeutic opportunity to treat neurodegenerative disorders and
aberrations in bone formation. Stimulation of the Wnt/b-catenin
pathway by compounds only in specific tissues is expected to
generate a better side-effect profile. We have identified small
molecule activators of Wnt/b-catenin signaling in a U2OS cell line
that did not activate this pathway in various other cell types from
different histogenic origin. The molecular target through which
the compounds activate b-catenin signaling has yet to be
determined, although several key regulators of b-catenin signaling,
including GSK3 and Frizzled receptors, were excluded.
Integrative approaches coupling protein interaction maps to
siRNA screening data have suggested that the components that
constitute the Wnt/b-catenin signaling machinery in a given cell
type are highly variable [21]. Our data confirm that small
molecule-mediated cell-type specific activation of Wnt/b-catenin
signaling can be achieved. However, elucidation of the molecular
target is essential to fully appreciate this finding, and is desirable
before these compounds are considered as a starting point for drug
discovery. A possible strategy for target identification is biotin-
labeling, followed by affinity capture of binding partners in cell
lysates. However, such approaches are generally more successful
with compounds that bind to their target with high affinity, while
screening of several hundreds of analogs did not reveal compounds
with potencies lower than 1 mM.
In conclusion, we have identified small molecule compounds
that activate Wnt/b-catenin signaling in a highly cell-type specific
Figure 3. Cpd1 and Cpd2 do not cause activation of Akt/PKB signaling in U2OS-EFC cells. U2OS-EFC cells were stimulated with vehicle,
100 nM insulin, 100 ng/ml platelet-derived growth factor (PDGF), 12 nM rmWnt-3a, 30 mM LiCl or 10 mM Cpd1, Cpd2 and CP-55940 for 30 min,
followed by cell lysis. Akt/protein kinase B (PKB) and glycogen synthase kinase 3b (GSK3b) phosphorylations at Ser473 and Ser9, respectively, were
analyzed by western blotting.
doi:10.1371/journal.pone.0019185.g003
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manner. Our data hold promise for the development of tissue-
specific b-catenin signaling activators.
Materials and Methods
Cell lines
HEK293T, U2OS, CHO-K1, LM-TK and HeLa cells were
obtained from the American Type Culture Collection (ATCC)
and cultured in DMEM F12 containing 10% fetal bovine serum
(FBS; Cambrex, Verviers, Belgium), 100 U/ml penicillin and
100 mg/ml streptomycin (Invitrogen, Breda, The Netherlands).
U2OS-Da-Nuc cells (DiscoveRx; Hannover, Germany) were
maintained in the same medium, supplemented with 150 mg/ml
hygromycin (Invitrogen). U2OS-EFC, U2OS-GR and HEK293-
EFC cells, the generation of which is described elsewhere [10],
were cultured in DMEM F12 supplemented with 10% FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, 150 mg/ml hygro-
mycin and 500 mg/ml geneticin (Invitrogen).
Figure 4. Cpd1 and Cpd2 do not activate Wnt/b-catenin signaling in HEK293 cells. (A,B) U2OS-Da-Nuc cells (parental to U2OS-EFC cells) (A)
and HEK293T cells (B) transiently transfected with SuperTOPflash reporter gene construct were stimulated with 12 nM rmWnt-3a or 10 mM Cpd1,
Cpd2 and CP-55940 for 5 hrs followed by measurement of luciferase activity. (C) HEK293T cells were stimulated with vehicle, 12 nM rmWnt-3a,
30 mM LiCl or 10 mM Cpd1, Cpd2 and CP-55940 for 3 hrs, followed by isolation of cytoplasmic protein fractions and probing of b-catenin and b-actin
using western blotting. (D) U2OS-EFC cells and HEK293 cells genetically engineered to complement b-galactosidase upon nuclear translocation of b-
catenin (HEK293-EFC cells) were stimulated with increasing concentrations of Cpd1 and Cpd2 or 12 nM rmWnt-3a for 3 hrs, followed by
measurement of b-galactosidase activity. (E) U2OS-Da-Nuc cells stably transfected with a vector coding for a-peptide-tagged human glucocorticoid
receptor (U2OS-GR cells) were treated with increasing doses of dexamethasone (Dex; a GR agonist) or Cpd1 for 3 hrs before measurement of b-
galactosidase activity. (F) U2OS-EFC cells were stimulated with 12 nM rmWnt-3a or 10 mM Cpd1 for several time points before measurement of b-
galactosidase activity.
doi:10.1371/journal.pone.0019185.g004
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LMW compounds and recombinant proteins
Synthetic organic low-molecular weight (LMW) compounds
were selected from the Merck Research Laboratories compound
collection (Oss, The Netherlands) based on previously determined
activity on various G protein-coupled receptor (GPCR) or protein
kinase targets. Recombinant mouse Wnt-3a (rmWnt-3a), recom-
binant human Wnt inhibitory factor-1 (WIF1) and recombinant
human Dickkopf-1 (rhDkk-1) were purchased from R&D Systems
(Abingdon, U.K.). Platelet-derived growth factor (PDGF) was
obtained from PeproTech (Rocky Hill, NJ).
b-Galactosidase fragment complementation assays
The b-catenin EFC assay was performed as described
previously [10].
Reporter gene assays
Luciferase assays on transiently transfected cells were performed
as described before [10]. The pTA-SuperTOPflash and pTA-
SuperFOPflash reporter gene constructs were provided by Prof.
dr. R.T Moon (University of Washington, WA, USA). p21xCRE-
luc was obtained from the VU University (Amsterdam, The
Netherlands). pTA-NFAT-luc was purchased from Clontech.
pMMTV-luc and pNGV1-GR were provided by Hans van der
Maaden (Merck Research Laboratories). For MMTV-luciferase
reporter gene experiments, pMMTV-luc and pNGV1-GR were
co-transfected in a 5:1 molar ratio.
Western blotting
Isolation of cytoplasmic fractions and total cell lysates, followed
by western blotting, was described previously [10]. The following
antibodies were used at the indicated dilutions: mouse anti-b-
catenin: 1:2000 (BD Transduction Laboratories; Lexington, KY),
mouse anti-b-actin: 1:5000 (Abcam; Cambridge, UK), rabbit-anti-
Akt: 1:1000, rabbit anti-GSK3b: 1:1000, rabbit anti-phospho-
Ser473 Akt: 1:1000, rabbit anti-phospho-Ser9 GSK3b: 1:1000,
rabbit anti-LRP6: 1:1000 and rabbit anti-phospho-Ser1490 LRP6:
1:1000 (Cell Signaling Technology; Danvers, MA), anti-mouse-
HRP conjugate: 1:2000 and anti-rabbit-HRP conjugate: 1:1000
(Promega; Leiden, The Netherlands).
qPCR analysis
Isolation of total mRNA and subsequent analysis of transcript
levels by qPCR was performed as described previously [22].
Data analysis
The concentration at which half-maximal activation of the cellular
response was reached (EC50 values) for rhDkk1 and rmWnt-3a dose
response curves was calculated from the expected molecular mass of
rhDkk-1 and rmWnt-3a (both 41 kDa) using Graphpad Prism 4.0
software. All data are represented as averages6 standard error in the
mean (SEM). Statistical significance of observed differences was
determined using Student’s t-test and indicated in the figures with
asterisks (*). P,0.05 was regarded as statistically significant.
Supporting Information
Figure S1 Cpd1 induces transcription of the b-catenin-
responsive gene axin2 in U2OS-Da-Nuc cells. U2OS-Da-
Nuc cells were treated with vehicle, 12 nM rmWnt-3a or 10 mM
Cpd1 for 8 hrs before analysis of axin2 mRNA levels relative to
the expression of the housekeeping gene TATA box-binding
protein (TAFII) by means of qPCR. Asterisk represent statistically
significant differences (p,0.05).
(TIF)
Figure S2 Schematic representation of the mode of
action of Cpd1 and Cpd2. A model of Wnt/b-catenin
signaling, in which activation of Frizzled receptors by Wnt-3a
leads to subsequent phosphorylation of LRP5/6, inhibition of
GSK3, b-catenin accumulation, b-catenin nuclear translocation
and b-catenin-dependent gene transcription. Cpd1 and Cpd2
activate Wnt/b-catenin signaling at the level of b-catenin
accumulation.
(TIF)
Figure S3 Structural analogs of Cpd1 and Cpd2 activate
Wnt/b-catenin signaling in U2OS-EFC cells. U2OS-EFC
cells were treated for 3 hrs with 10 nM rmWnt-3a or 10 mM of
Cpd1-5, before measurement of b-galactosidase activity.
(TIF)
Figure S4 Cpd1 and Cpd2 do not activate Wnt/b-catenin
signaling in several commonly used cell lines from
different origins. HeLa (A), CHO-k1 (B), Saos-2 (C), UMR106
(D) and U2OS cells derived from ATCC (E) were transiently
transfected with TOPflash reporter gene construct and stimulated
with 10 mM Cpd1, Cpd2 or CP55940 or 12 nM rmWnt-3a for
5 hrs prior to measurement of luciferase activity.
(TIF)
Figure S5 Cpd1 activates SuperTOPflash, but not
CREB-, NFAT- and GR-dependent reporter gene activity
in U2OS-Da-Nuc cells. U2OS-Da-Nuc cells were transiently
transfected with vectors encoding luciferase under the transcrip-
tional control of (A) b-catenin (SuperTOPflash), (B) CREB
(21xCRE-luc), (C) NFAT/Ca2+ (NFAT-luc) and (D) GR
(MMTV-luc). Cells were stimulated with ascending concentrations
of Cpd1 and reference agonists: (A) 10 nM rmWnt-3a, (B) 10 mM
isoproterenol, an agonist for endogenously expressed Gs-coupled
b2 adrenergic receptors, (C) a combination of 100 nM phorbol 12-
myristate 13-acetate (PMA) and 100 nM thapsigargin (Thaps),
which activate protein kinase C and Ca2+-signaling, respectively,
and (D) 1 mM of the GR agonist dexamethasone (Dex).
(TIF)
Figure S6 Cpd1 does not activate b-galactosidase activ-
ity in a CHO cell line genetically engineered to couple
recruitment of the scaffolding protein b-arrestin2 to the
human parathyroid hormone receptor 1 (hPTH1R).
CHO-PTH1R cells were stimulated with increasing concentra-
tions of Cpd1 or with 100 nM human PTH1-34 for 90 min,
followed by measurement of b-galactosidase activity.
(TIF)
Figure S7 The increase in b-galactosidase activity in
U2OS-EFC cells following treatment with Cpd1 has a
profile that is similar to that observed for U2OS-EFC
cells treated with LiCl. U2OS-EFC cells were treated with
10 mM Cpd1 or 30 mM LiCl for several time periods before
measurement of b-galactosidase activity.
(TIF)
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